WO2020022975A3 - New pharmaceutical compositions in the treatment of copd - Google Patents
New pharmaceutical compositions in the treatment of copd Download PDFInfo
- Publication number
- WO2020022975A3 WO2020022975A3 PCT/TR2018/000134 TR2018000134W WO2020022975A3 WO 2020022975 A3 WO2020022975 A3 WO 2020022975A3 TR 2018000134 W TR2018000134 W TR 2018000134W WO 2020022975 A3 WO2020022975 A3 WO 2020022975A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- pharmaceutical compositions
- copd
- new pharmaceutical
- new
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to pharmaceutical compositions comprising N-Acetycysteine and mannitol for use in the treatment of COPD attacks.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2017/22950A TR201722950A2 (en) | 2017-12-29 | 2017-12-29 | New pharmaceutical compositions in the treatment of COPD. |
| TR2017/022950 | 2017-12-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2020022975A2 WO2020022975A2 (en) | 2020-01-30 |
| WO2020022975A3 true WO2020022975A3 (en) | 2020-02-27 |
Family
ID=67901361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2018/000134 WO2020022975A2 (en) | 2017-12-29 | 2018-12-28 | New pharmaceutical compositions in the treatment of copd |
Country Status (2)
| Country | Link |
|---|---|
| TR (1) | TR201722950A2 (en) |
| WO (1) | WO2020022975A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201800007928A1 (en) * | 2018-08-07 | 2020-02-07 | Sofar Spa | Composition containing a mucolytic agent for the treatment of mucus hypersecretion and a device for its dosage |
| CN116098886B (en) * | 2023-01-12 | 2024-04-26 | 澳门科技大学 | Pharmaceutical composition and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006030221A1 (en) * | 2004-09-15 | 2006-03-23 | Cipla Limited | Pharmaceutical composition comprising a betaminetic agent and a mucolytic agent |
| US20070065373A1 (en) * | 2003-09-15 | 2007-03-22 | Vectura Ltd. | Mucoactive agents for treating a pulmonary disease |
| WO2011069197A1 (en) * | 2009-12-08 | 2011-06-16 | The University Of Sydney | Inhalable formulations |
-
2017
- 2017-12-29 TR TR2017/22950A patent/TR201722950A2/en unknown
-
2018
- 2018-12-28 WO PCT/TR2018/000134 patent/WO2020022975A2/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070065373A1 (en) * | 2003-09-15 | 2007-03-22 | Vectura Ltd. | Mucoactive agents for treating a pulmonary disease |
| WO2006030221A1 (en) * | 2004-09-15 | 2006-03-23 | Cipla Limited | Pharmaceutical composition comprising a betaminetic agent and a mucolytic agent |
| WO2011069197A1 (en) * | 2009-12-08 | 2011-06-16 | The University Of Sydney | Inhalable formulations |
Non-Patent Citations (3)
| Title |
|---|
| ODZIOMEK, M. ET AL.: "Conception, preparation and properties of functional carrier particles for pulmonary drug delivery", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 433, no. 1-2, 5 January 2012 (2012-01-05), pages 51 - 59, XP028493598 * |
| SNIJDERS, D. ET AL.: "Inhaled mucoactive drugs for treating non-cystic fibrosis bronchiectasis in children", INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, vol. 26, no. 2, pages 529 - 534, XP055687438 * |
| WEINBROUM, A. A. ET AL.: "Concomitant administration of mannitol and N-acetylcysteine for the prevention of lung reperfusion injury", JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, vol. 60, no. 6, 2006, pages 1290 - 1296, XP055687440 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020022975A2 (en) | 2020-01-30 |
| TR201722950A2 (en) | 2019-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015011898A (en) | Pyrazolo compounds and uses thereof. | |
| WO2016011306A3 (en) | Terminal modifications of polynucleotides | |
| WO2016149401A3 (en) | Piperazine carbamates and methods of making and using same | |
| IL271807A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| WO2015120062A3 (en) | Therapeutic compounds and compositions | |
| IL261444A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| EP4218736A3 (en) | Compositions comprising 15-hepe | |
| WO2015106215A3 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| WO2016142708A3 (en) | Pharmaceutical composition | |
| EP3651801A4 (en) | Compositions and methods for the treatment of fungal infections | |
| WO2018226992A8 (en) | Tau aggregation inhibitors | |
| BR112015013675A2 (en) | compositions comprising vortioxetine and donepezil | |
| WO2016007540A3 (en) | Compositions and methods for treating dengue virus infection | |
| EP3835311C0 (en) | Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient | |
| EA201691792A1 (en) | PHARMACEUTICAL COMPOSITIONS BASED ON VILDAGLIPTINA | |
| WO2020022975A3 (en) | New pharmaceutical compositions in the treatment of copd | |
| EP3706767A4 (en) | Compositions and methods for the treatment of allergy | |
| WO2016109002A3 (en) | Methods and compositions for the treatment of radiation-related disorders | |
| EP3600277A4 (en) | Compositions for the treatment of drug-resistant tumors and methods of use thereof | |
| WO2016069542A3 (en) | Lactone compounds and methods of making and using same | |
| WO2019103875A3 (en) | Methods of using and compositions containing dulaglutide | |
| PH12019500180A1 (en) | Compositions for the treatment of pulmonary fibrosis | |
| HK1257448A1 (en) | Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof | |
| PH12017501943A1 (en) | Influenza virus neutralizing peptidomimetic compounds | |
| WO2016109361A3 (en) | 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18927968 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 18927968 Country of ref document: EP Kind code of ref document: A2 |